Key points are not available for this paper at this time.
mTOR inhibitor and corticosteroids represent a favorable immunosuppressive regimen for KTRs with advanced CSCC receiving immunotherapy. This combination resulted in durable antitumor responses with no kidney rejection events (funded by Regeneron Pharmaceuticals ClinicalTrials.gov identifier: NCT04339062).
Hanna et al. (Mon,) studied this question.